News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Subscribe To Our Newsletter & Stay Updated
